Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Carboplatin (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Olomorasib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Adenoid cystic carcinoma; Brain metastases; Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Intestinal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms KRAS G12C
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 03 Aug 2026 According to an Eli Lilly and Company media release, based on encouraging preliminary results from this trial ,the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test.
  • 29 May 2026 Status changed from recruiting to active, no longer recruiting.
  • 13 Oct 2025 According to an Eli Lilly and Company media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting, taking place October 17-21 in Berlin, Germany.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top